| Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries JJJ Leahy, BT Golding, RJ Griffin, IR Hardcastle, C Richardson, ... Bioorganic & medicinal chemistry letters 14 (24), 6083-6087, 2004 | 458 | 2004 |
| Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor TG Davies, J Bentley, CE Arris, FT Boyle, NJ Curtin, JA Endicott, ... Nature structural biology 9 (10), 745-749, 2002 | 278 | 2002 |
| Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach IR Hardcastle, X Cockcroft, NJ Curtin, MD El-Murr, JJJ Leahy, M Stockley, ... Journal of medicinal chemistry 48 (24), 7829-7846, 2005 | 200 | 2005 |
| Selective Benzopyranone and Pyrimido[2,1-a]isoquinolin-4-one Inhibitors of DNA-Dependent Protein Kinase: Synthesis, Structure−Activity Studies, and … RJ Griffin, G Fontana, BT Golding, S Guiard, IR Hardcastle, JJJ Leahy, ... Journal of medicinal chemistry 48 (2), 569-585, 2005 | 197 | 2005 |
| Small-molecule inhibitors of the MDM2-p53 protein− protein interaction based on an isoindolinone scaffold IR Hardcastle, SU Ahmed, H Atkins, G Farnie, BT Golding, RJ Griffin, ... Journal of medicinal chemistry 49 (21), 6209-6221, 2006 | 175 | 2006 |
| Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein− protein interaction: structure− activity studies leading to improved potency IR Hardcastle, J Liu, E Valeur, A Watson, SU Ahmed, TJ Blackburn, ... Journal of medicinal chemistry 54 (5), 1233-1243, 2011 | 161 | 2011 |
| Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen MR Osborne, A Hewer, IR Hardcastle, PL Carmichael, DH Phillips Cancer research 56 (1), 66-71, 1996 | 159 | 1996 |
| Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer K Coffey, TJ Blackburn, S Cook, BT Golding, RJ Griffin, IR Hardcastle, ... Public Library of Science 7 (10), e45539, 2012 | 158 | 2012 |
| N2-substituted O 6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2 IR Hardcastle, CE Arris, J Bentley, FT Boyle, Y Chen, NJ Curtin, ... Journal of medicinal chemistry 47 (15), 3710-3722, 2004 | 153 | 2004 |
| 2, 6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK) JJ Hollick, BT Golding, IR Hardcastle, N Martin, C Richardson, ... Bioorganic & medicinal chemistry letters 13 (18), 3083-3086, 2003 | 150 | 2003 |
| Designing inhibitors of cyclin-dependent kinases IR Hardcastle, BT Golding, RJ Griffin Annual review of pharmacology and toxicology 42 (1), 325-348, 2002 | 134 | 2002 |
| Isoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction IR Hardcastle, SU Ahmed, H Atkins, AH Calvert, NJ Curtin, G Farnie, ... Bioorganic & medicinal chemistry letters 15 (5), 1515-1520, 2005 | 130 | 2005 |
| Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction C Riedinger, JA Endicott, SJ Kemp, LA Smyth, A Watson, E Valeur, ... Journal of the American Chemical Society 130 (47), 16038-16044, 2008 | 121 | 2008 |
| Inhibition of protein prenylation by metabolites of limonene IR Hardcastle, MG Rowlands, AM Barber, RM Grimshaw, MK Mohan, ... Biochemical pharmacology 57 (7), 801-809, 1999 | 117 | 1999 |
| Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation M Pennati, AJ Campbell, M Curto, M Binda, YZ Cheng, LZ Wang, N Curtin, ... Molecular cancer therapeutics 4 (9), 1328-1337, 2005 | 106 | 2005 |
| Cyclin-dependent kinase (CDK) inhibitors: structure–activity relationships and insights into the CDK-2 selectivity of 6-substituted 2-arylaminopurines CR Coxon, E Anscombe, SJ Harnor, MP Martin, B Carbain, BT Golding, ... Journal of medicinal chemistry 60 (5), 1746-1767, 2017 | 101 | 2017 |
| Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes DH Phillips, PL Carmichael, A Hewer, KJ Cole, IR Hardcastle, GK Poon, ... Carcinogenesis 17 (1), 89-94, 1996 | 100 | 1996 |
| Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure− activity relationships for DNA-dependent protein kinase inhibition … JJ Hollick, LJM Rigoreau, C Cano-Soumillac, X Cockcroft, NJ Curtin, ... Journal of medicinal chemistry 50 (8), 1958-1972, 2007 | 99 | 2007 |
| Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2 KL Sayle, J Bentley, FT Boyle, AH Calvert, Y Cheng, NJ Curtin, ... Bioorganic & medicinal chemistry letters 13 (18), 3079-3082, 2003 | 92 | 2003 |
| An evaluation of the ability of pifithrin-α and-β to inhibit p53 function in two wild-type p53 human tumor cell lines MI Walton, SC Wilson, IR Hardcastle, AR Mirza, P Workman Molecular cancer therapeutics 4 (9), 1369-1377, 2005 | 89 | 2005 |
Martin NobleProfessor of Structural Biology and Anticancer Drug DesignVerified email at ncl.ac.uk
